1. Introduction {#s0005}
===============

Cervical cancer is the fourth most common cancer affecting women worldwide ([@bb0010]). Globally, there were 527,600 new cases with 265,700 deaths in 2012. Over 85% of cases and 87% of deaths occur in low-resource countries ([@bb0055]). Central and South America are among the regions with the highest incidence ([@bb0010]), and access to internationally accepted standards of care is often inadequate.

In Honduras, cancer of the uterine cervix is the most commonly diagnosed neoplasm in women. Cervical cancer represents 36.4% of female cancers nationally, and is the principal cause of cancer death in women. In Honduras, cervical cancer most commonly affects women aged 30--69 years and patients are frequently diagnosed with locally advanced disease ([@bb0045]). In 2009, 23% of all cancer cases treated at the Department of Oncology at the Hospital General San Felipe (HGSF) were cervical cancer.

Both surgery and radiotherapy (RT) may be offered as primary treatment in stage I-IIA disease as both treatment options demonstrated similar cure rates in this patient population ([@bb0025]). Standard treatment for patients with more advanced disease is concurrent chemotherapy and external beam RT (EBRT) followed by brachytherapy ([@bb0005], [@bb0030]). Unfortunately this standard treatment is not available in many low-resource settings.

Brachytherapy, a fundamental pillar of treatment for locally advanced cervical cancer, is not available at the National Cancer Center at The Hospital of General San Felipe in Honduras. For this reason, these patients are recommended for EBRT with or without concurrent chemotherapy are utilized. Often, the availability of chemotherapeutic agents is unreliable and EBRT is given alone. Following treatment, those patients with a complete clinical response (cCR) undergo extrafascial hysterectomy in lieu of brachytherapy 4--6 weeks after completion of treatment. Our goal was to evaluate clinical response rates among patients treated in the Department of Oncology at the Hospital General San Felipe (HGSF), who received either EBRT alone or concurrent chemoradiation (CCRT) for locally advanced cervical cancer.

2. Materials and methods {#s0010}
========================

After approval from the internal review board, a retrospective chart review was performed for 165 patients who received primary treatment with either EBRT or CCRT for a histologically confirmed diagnosis of cervical cancer at the HGSF from January 2008 to June 2011. Patients older than the age of 20 and younger than the age of 70 were included. Seventy Gray (Gy) of EBRT with or without chemotherapy were given to all the patients. None of the patients received brachytherapy treatment. Patients were deemed to have a clinical complete response (cCR) to RT ± chemotherapy if there was no residual tumor on clinical physical examinations. These patients who had cCR underwent extrafascial hysterectomy 6 weeks after completion of radiation therapy. Data analysis included age, clinical stage, histologic types, size of tumor, date of diagnosis, duration and methods of treatment, and clinical response.

3. Statistical analysis {#s0015}
=======================

The primary endpoint of this study was complete clinical response (cCR) upon completion of EBRT and CCRT. Variables with a non-normal distribution were expressed as median and range. For categorical variables, the χ^2^ test and the Fisher exact test were used. The *t*-test was used to compare variables that were normally distributed. Comparisons of variables not normally distributed were made by the Mann-Whitney *U* test. *P* values are the result of 2-sided tests and *P* \< 0.05 was considered to indicate a statistically significant difference. Statistical analysis was performed with software (SPSS, version 19.0; IBM Corp, Armonk, NY).

4. Results {#s0020}
==========

Patients were collected from January 2008 through June 2011, and 165 women were included in the study. All patients received EBRT or CCRT for stage IB2 through IIIB cervical carcinoma. Ninety patients (54.5%) received EBRT alone and 75 (45.5%) patients received CCRT. The median age, stage, tumor size, and histology were similar in both groups. The treatment duration was significantly longer in the patients who received non-platinum based chemotherapy ([Table 1](#t0005){ref-type="table"}).

Complete clinical response (cCR) rates decreased with advanced stage ([Table 2](#t0010){ref-type="table"}). Stage IIB was the most common stage at diagnosis in both groups with 44/90 (49%) patients in the EBRT group and 38/75 (51%) patients in the CCRT group respectively. The cCR was significantly lower among stage IIB and IIIB patients treated with CCRT when compared with EBRT. Patients with IB2 cervical cancer did equally well and all achieved cCR. Tumor size was \> 4 cm in 142 (86.1%) of 165 patients. All patients with tumors \< 4 cm experienced cCR, compared to 72 (68.6%) in 142 patients with tumor size \> 4 cm. Histologic subtype did not appear to be a prognostic indicator: 135 (81.8%) of tumors were squamous cell carcinomas, 30 (18.2%) were adenocarcinomas. Of the 30 cases with adenocarcinoma, 25 (83.3%) underwent treatment with EBRT and 5 (16.7%) received CCRT; of the 135 squamous cell carcinoma (SCC) cases, 73 (54.1%) received EBRT and 62 (45.9%) received CCRT. Overall 76/135 patients with SCC demonstrated 56.3% cCR rate, which was comparable to the cCR of 18/30 (60%) among adenocarcinoma cases. The cCR of 33.3% were significantly lower in both SCC and adenocarcinoma patients who received CCRT comparing to the cCR of 76.7% for those who received EBRT ([Table 2](#t0010){ref-type="table"}).

Overall, cCR was seen in 95 patients (57.6%) in both groups combined. Of the patients who were treated with CCRT, 23 patients (33.3%) were treated with cisplatin (40 mg/m^2^ weekly for 5 cycles) chemotherapy and the remaining 52 patients (66.7%) received 5-fluourouracil (700 mg/m^2^ day 1--4 every 3 weeks), capecitabine (1000 mg/m^2^ twice daily on days 1 to 14, every 3 weeks for 2 cycles) or gemcitabine (1000 mg/m^2^ on days 1 and 8, every 3 weeks for 2 cycles). Of the 90 patients who received EBRT alone, 70 patients had a cCR of 77.8% and underwent adjuvant hysterectomy. In the CCRT group, 25 patients (33%) had a cCR ([Fig. 1](#f0005){ref-type="fig"}A). The 25 patients that received cisplatin based therapy demonstrated an 80% cCR rate ([Fig. 1](#f0005){ref-type="fig"}B). Residual tumors were found in 50% of the patients who underwent hysterectomy in both groups.

One hundred and fifteen (69.5%) of patients completed their treatments within 60 days. The cCR was 65.2% in this group of patients. The treatment duration was significantly longer in the patients who received non-platinum based chemotherapy ([Table 1](#t0005){ref-type="table"}). Of the 23 patients who received CCRT with cisplatin, only 5 patients had their treatments extended beyond 60 days. The majority of the CCRT patients that had treatment longer than 60 days received other agents (5-fluorouracil, capecitabine and gemcitabine). These patients had a poor cCR of 31% ([Fig. 1](#f0005){ref-type="fig"}B). There were no differences between the two groups in the incidence of grade 3 and 4 toxicities: 13% in the EBRT group and 19% in the CCRT groups (NS).

5. Discussion {#s0025}
=============

The burden of cervical cancer continues to fall most heavily on low- and middle-income countries largely due to lack of screening and treatment modalities. In a high-resource setting, the standard of care for locally advanced cervical cancer is CCRT with cisplatin based chemotherapy followed by brachytherapy ([@bb0005], [@bb0030], [@bb0060], [@bb0065], [@bb0050]). Although it has previously been demonstrated that non-platinum based chemotherapy regimens are less effective ([@bb0005], [@bb0030], [@bb0065], [@bb0050], [@bb0070]), platinum-based chemotherapy may not be readily available in low-resource settings. This was the case in the patient population at HGSF in Honduras, and as would be expected, patients who received non-platinum based therapy had lower response rates. Approximately two-thirds of the patients in this cohort received non-platinum based CCRT with only a 31% response rate. Among the patients in this study who received platinum based therapy, the response rates were comparable to those cited in the literature. This emphasizes the importance of platinum based regimens in the treatment of locally advanced cervical cancer.

Brachytherapy following concurrent chemotherapy and EBRT is considered standard of care, but brachytherapy is not available at the HGSF and we therefore substituted adjuvant extrafascial hysterectomy for this modality. The role of adjuvant extrafascial hysterectomy has been explored by the Gynecologic Oncology Group (GOG) in patients with bulky FIGO stage IB invasive carcinoma of the cervix. They reported on a cohort of patients with tumors measuring \> 4 cm who were randomized to extrafascial hysterectomy or observation following EBRT and brachytherapy (chemotherapy was not administered in either arm). In this cohort there was a lower rate of local relapse (14% vs. 27% at 5 years) in the hysterectomy group. However, overall survival outcomes were not statistically different between the two groups ([@bb0020]). Although our patients did not have brachytherapy available to them, we felt that this GOG data supports the use of adjuvant extrafascial hysterectomy in these patients. Our study was not designed to assess survival, but this will be the subject of future analysis.

Factors associated with treatment failure in patients with cervical cancer include large volume of disease and treatment prolongation. The best response was seen among smaller tumors at less advanced stages in our patient population. All patients with tumors measuring 4 cm or less had a favorable response. In comparison, only 50.7% of patients with tumors measuring \> 4 cm had a clinical complete response. With regards to treatment time, it has been shown that a protracted treatment course can be deleterious to overall outcomes ([@bb0015], [@bb0040], [@bb0035]). One group demonstrated that survival and pelvic control at 5 years decreased 0.6% and 0.7%, respectively, for each additional day of treatment beyond 55 days ([@bb0040]). In our patients treatment can be delayed for reasons including lack of financial resources, difficulty with transportation and various socioeconomic stressors. These treatment delays likely contribute to a reduction in the cCR and once radiotherapy is initiated every effort should be made not to delay treatment.

Cervical cancer is the most commonly diagnosed cancer among women in Honduras. To this end, these women deserve the opportunity to receive a therapy with the goal of achieving cure. Efforts should be made to treat women with locally advanced cervical cancer with cisplatin-based CCRT. Treatment should not be delayed once it has been initiated and if cisplatin is not available, radiotherapy should be offered rather than delay treatment while awaiting availability of chemotherapy agents.
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###### 

Patient characteristics.

Table 1

                                  EBRT N = 90 (%)   CCRT N = 75 (%)   *P*-value
  ------------------------------- ----------------- ----------------- -----------
  Median age by years (range)     47 (25--64)       44 (27--63)       NS
  Stage                                                               0.90
   IB2                            16 (27)           12 (16)           
   IIA                            10 (11)           7 (9)             
   IIB                            44 (49)           38 (51)           
   IIIA                           0 (0)             0 (0)             
   IIIB                           20 (22)           18 (24)           
  Tumor sizes                                                         0.51
   ≤ 4 cm                         14 (16)           9 (12)            
   \> 4 cm                        76 (84)           66 (88)           
  Histology                                                           0.79
  Squamous                        73 (81)           62 (86)           
  Adenocarcinoma                  17 (19)           13 (17)           
  Treatment duration \< 60 days   85 (94)           30 (40)           \< 0.05

(EBRT: external beam radiotherapy; CCRT: concurrent chemoradiation).

###### 

Complete clinical response rates by stage, tumor size, and histology.

Table 2

  ------------------------------------------------------------------------------------------
                    EBRT (n = 90)\         CCRT (n = 75) number responded (%)   *P* value
                    number responded (%)                                        
  ----------------- ---------------------- ------------------------------------ ------------
  FIGO stage                                                                    

   IB2              13/13 (100)            12/12 (100)                          NS

   IIA              7/9 (78)               3/6 (50)                             NS

   IIB              38/49 (78)             9/41 (22)                            \< 0.00001

   IIIB             12/19 (63)             1/16 (6)                             0.0005

  Tumor size                                                                    

   ≤ 4 cm           14/14 (100)            9/9 (100)                            NS

   \> 4 cm          56/76 (74)             16/66 (24)                           \< 0.00001

  Histology                                                                     

   Squamous         56/73 (77)             20/62 (32)                           \< 0.00001

   Adenocarcinoma   13/17 (77)             5/13 (39)                            NS
  ------------------------------------------------------------------------------------------

FIGO: International Federation of Gynecology and Obstetrics 2009.
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